EPCAM and hepatocellular carcinoma: We evaluated the effect of sorafenib on cell proliferation in the EpCAM+ and CD90+ HCC cell lines; sorafenib treatment (10 μM) suppressed the proliferation of the CD90+ HCC cell lines (HLE, HLF, and SK-Hep-1) more strongly compared with the EpCAM+ HCC cell lines (HuH1, HuH7, and Hep3B) and this was statistically significant (P < 0.05) (Fig. 1D).